Cargando…
Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration
OBJECTIVE: To evaluate the performance of the individual Positive and Negative Symptom Scale (PANSS) items, and to assess the feasibility of using a shortened version of the PANSS as an alternative regulatory endpoint for evaluating the efficacy of drugs to treat schizophrenia. DESIGN: Data from 32...
Autores principales: | Gopalakrishnan, Mathangi, Farchione, Tiffany, Mathis, Mitchell, Zhu, Hao, Mehta, Mehul, Uppoor, Ramana, Younis, Islam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175851/ https://www.ncbi.nlm.nih.gov/pubmed/36101554 http://dx.doi.org/10.1176/appi.prcp.20200003 |
Ejemplares similares
-
A Proposal of Conducting Bioequivalence Trials with Gastric pH Modulators for Two Oral Formulations Demonstrating Different Dissolution Profiles at Elevated pH
por: Zhu, Hao, et al.
Publicado: (2019) -
Mortality in schizophrenia: a measurable clinical endpoint
por: Bushe, Chris J, et al.
Publicado: (2010) -
Importance of achieving the composite endpoints in diabetes
por: Unnikrishnan, Ambika Gopalakrishnan, et al.
Publicado: (2013) -
Model‐based approach to identify predictors of paclitaxel‐induced myelosuppression in “real‐world” administration
por: Salem, Ahmed M., et al.
Publicado: (2023) -
An alternative approach for estimating the number needed to treat for survival endpoints
por: Yang, Zhao, et al.
Publicado: (2019)